<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920749</url>
  </required_header>
  <id_info>
    <org_study_id>316-2336/KK15</org_study_id>
    <nct_id>NCT02920749</nct_id>
  </id_info>
  <brief_title>Study of Anaesthesia Costs and Recovery Profiles</brief_title>
  <acronym>SACRP</acronym>
  <official_title>Recovery Profiles and Costs in Sevoflurane and Propofol Based Anaesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the perioperative hemodynamic parameters, recovery
      profiles and cost containment of sevoflurane and propofol based general anesthesia for
      otorhinolaryngeal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sevoflurane and propofol are two basic drugs in the maintenance of anaesthesia. In this study
      we compared the perioperative hemodynamic parameters, recovery profiles and cost containment
      of sevoflurane and propofol based general anaesthesia for otorhinolaryngeal surgery. Patients
      were equally divided into four anaesthetic subgroups. In groups A and C anaesthesia was based
      on sevoflurane or propofol, respectively, without bispectral index (BIS) and train-of-for
      monitor (TOF) monitoring. In groups B and D anaesthesia was based on sevoflurane or propofol,
      respectively, with BIS and TOF monitoring. Drug consumption, recovery profiles and
      anaesthesia costs were analysed.

      ECG, main arterial pressure (MAP), heart rate, oxygen saturation of peripheral haemoglobin
      (SpO2), pressure of end-tidal carbon dioxide was monitored continuously and registered at 5
      min intervals during anaesthesia. Each group received propofol for anaesthesia induction. In
      group A and B anaesthesia was maintained with sevoflurane, in groups C and D with propofol.
      In groups B and D the depth of anaesthesia (BIS® Quatro Brain Monitoring Sensor, Covidien)
      and the neuromuscular blocking status (Infinity®, Trident® NMT SmartPod®, Dräger Medical)
      were monitored too. BIS and TOF values were recorded at 5 min intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Consumption</measure>
    <time_frame>at induction one dose and during anaesthesia mg/1 hour</time_frame>
    <description>drugs of sevoflurane or total intravenous anaesthesia without or with BIS and TOF monitoring : fentanyl, sevoflurane, propofol 1%, atracurium in milligrams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Costs of Anaesthesia</measure>
    <time_frame>1 hour</time_frame>
    <description>total cost of drugs (midazolam, propofol 1%, sevoflurane, atracurium, diclofenac, nalbuphin and antidotes) and disposable cost in euros</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Anaesthesia</condition>
  <arm_group>
    <arm_group_label>Sevoflurane group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol group C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol group D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane group A</intervention_name>
    <description>In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was adjusted for the same MAP range.</description>
    <arm_group_label>Sevoflurane group A</arm_group_label>
    <other_name>Sevorane anaesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane group B</intervention_name>
    <description>In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.</description>
    <arm_group_label>Sevoflurane group B</arm_group_label>
    <other_name>Sevorane anaesthesia with BIS and TOF monitoring</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol group C</intervention_name>
    <description>In this group anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol dosing was adjusted for the same MAP range.</description>
    <arm_group_label>Propofol group C</arm_group_label>
    <other_name>Propofol anaesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol group D</intervention_name>
    <description>In this group anaesthesia was maintained with propofol. Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.</description>
    <arm_group_label>Propofol group D</arm_group_label>
    <other_name>Propofol anaesthesia with BIS and TOF monitoring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status grade I or II who were scheduled for elective
             otorhinolaryngological surgery.

        Exclusion Criteria:

          -  Individuals with a history of bronchial asthma, chronic obstructive pulmonary disease,
             epilepsy, psychiatric illness, cerebrovascular or congenital neuromuscular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Csaba Loibl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology and Intensive Therapy, University of Pecs, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zoltan Vamos, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology and Intensive Therapy, University of Pecs, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabor Woth, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology and Intensive Therapy, University of Pecs, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lajos Bogar, MD, PhD, DSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology and Intensive Therapy, University of Pecs, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laszlo Lujber, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Otorhinolaryngology, University of Pecs, Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tímea Bocskai</name>
      <address>
        <city>Pecs</city>
        <state>Ifjusag Street 13.</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <results_first_submitted>October 11, 2016</results_first_submitted>
  <results_first_submitted_qc>October 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2016</results_first_posted>
  <last_update_submitted>February 4, 2018</last_update_submitted>
  <last_update_submitted_qc>February 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pecs</investigator_affiliation>
    <investigator_full_name>Timea Bocskai</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>anaesthesia</keyword>
  <keyword>costs</keyword>
  <keyword>recovery profiles</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data of primary outcome measures will be made available within one month of study completion</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this study we compared the perioperative hemodynamic parameters, recovery profiles and cost containment of sevoflurane and propofol based general anaesthesia with controlled hypotension for otorhinolaryngeal surgery.</recruitment_details>
      <pre_assignment_details>We studied patients with ASA physical status I or II, their age between was between 18 and 65 years. Individuals with a history of pulmonary, psychiatric, cerebrovascular or congenital neuromuscular disease were excluded from the study. Patients were blocked randomised to one of four anaesthetic treatment groups with closed envelops.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane and fentanyl dosing was adjusted for the same MAP range for controlled hypotension within 60-85 mmHg. Atracurium was administered at regular intervals.</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. The depth of anaesthesia (BIS® Quatro Brain Monitoring Sensor, Covidien) and the neuromuscular blocking status (Infinity®, Trident® NMT SmartPod®, Dräger Medical) was monitored too. Sevoflurane and fentanyl dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg. Neuromuscular blocking was maintained with a TOF monitor at the level of one or no response.</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>Anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol and fentanyl dosing was adjusted for the same MAP range. Atracurium was administered at regular intervals.</description>
        </group>
        <group group_id="P4">
          <title>Group D</title>
          <description>In this group anaesthesia was maintained with propofol. The depth of anaesthesia (BIS® Quatro Brain Monitoring Sensor, Covidien) and the neuromuscular blocking status (Infinity®, Trident® NMT SmartPod®, Dräger Medical) was monitored too. Propofol and fentanyl dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg. Neuromuscular blocking was maintained with a TOF monitor at the level of one or no response.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>General anaesthesia was maintained with sevoflurane.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Anaesthesia was maintained with sevoflurane and the depth of anaesthesia (BIS® Quatro Brain Monitoring Sensor, Covidien) and the neuromuscular blocking status (Infinity®, Trident® NMT SmartPod®, Dräger Medical) was monitored too.</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>General anaesthesia was maintained with propofol.</description>
        </group>
        <group group_id="B4">
          <title>Group D</title>
          <description>Anaesthesia was maintained with propofol and the depth of anaesthesia (BIS® Quatro Brain Monitoring Sensor, Covidien) and the neuromuscular blocking status (Infinity®, Trident® NMT SmartPod®, Dräger Medical) was monitored too.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Consumption</title>
        <description>drugs of sevoflurane or total intravenous anaesthesia without or with BIS and TOF monitoring : fentanyl, sevoflurane, propofol 1%, atracurium in milligrams</description>
        <time_frame>at induction one dose and during anaesthesia mg/1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Fentanyl consumption was studied during sevoflurane anaesthesia. It was registered in milligram.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Fentanyl consumption was studied during sevoflurane anaesthesia with BIS and TOF monitoring. It was registered in milligram.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Fentanyl consumption was studied during total intravenous anaesthesia. It was registered in milligram.</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Fentanyl consumption was studied during total intravenous anaesthesia with BIS and TOF monitoring. It was registered in milligram.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Consumption</title>
          <description>drugs of sevoflurane or total intravenous anaesthesia without or with BIS and TOF monitoring : fentanyl, sevoflurane, propofol 1%, atracurium in milligrams</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fentanyl at induction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0983" spread="0.0091"/>
                    <measurement group_id="O2" value="0.1033" spread="0.0183"/>
                    <measurement group_id="O3" value="0.0991" spread="0.0046"/>
                    <measurement group_id="O4" value="0.0992" spread="0.0103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>propofol at induction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.3" spread="46.9"/>
                    <measurement group_id="O2" value="166.4" spread="35.2"/>
                    <measurement group_id="O3" value="194.3" spread="18.9"/>
                    <measurement group_id="O4" value="147.3" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>atracurium at induction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="4.2"/>
                    <measurement group_id="O2" value="37.3" spread="6.7"/>
                    <measurement group_id="O3" value="36.0" spread="5.7"/>
                    <measurement group_id="O4" value="37.7" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fentanyl during anaesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0546" spread="0.0269"/>
                    <measurement group_id="O2" value="0.0598" spread="0.0389"/>
                    <measurement group_id="O3" value="0.0898" spread="0,0428"/>
                    <measurement group_id="O4" value="0.0947" spread="0.0340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sevoflurane during anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11400" spread="2800"/>
                    <measurement group_id="O2" value="14800" spread="12400"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>propofol during anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="1185.5" spread="320.9"/>
                    <measurement group_id="O4" value="1082.1" spread="297.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>atracurium during anaesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="3.7"/>
                    <measurement group_id="O2" value="7.4" spread="4.7"/>
                    <measurement group_id="O3" value="8.5" spread="4.7"/>
                    <measurement group_id="O4" value="8.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was carried out with SPSS version 21 for Windows (IBM Corporation) software. All data are expressed as means ± SD. Mann-Whitney test was performed to assess the differences between patient subgroups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The P value less than 0.05 was considered to be significant. With type I α = 5% and with type II (power) of 90%, we therefore needed 27 patients/group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Costs of Anaesthesia</title>
        <description>total cost of drugs (midazolam, propofol 1%, sevoflurane, atracurium, diclofenac, nalbuphin and antidotes) and disposable cost in euros</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Drugs at induction were: fentanyl, propofol 1%, atracurium. Anaesthesia was maintained with sevoflurane, fentanyl and atracurium.
Cost was calculated in euros/1 hour. Disposable cost was calculated in euros.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Drugs at induction were: fentanyl, propofol 1%, atracurium. Anaesthesia was maintained with sevoflurane, fentanyl and atracurium.
Cost was calculated in euros/1 hour. Disposable cost was calculated in euros. In this group BIS sensor and TOF monitoring was used.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Drugs at induction were: fentanyl, propofol 1%, atracurium. Anaesthesia was maintained with propofol 1%, fentanyl and atracurium.
Cost was calculated in euros/1 hour. Disposable cost was calculated in euros.</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Drugs at induction were: fentanyl, propofol 1%, atracurium. Anaesthesia was maintained with propofol, fentanyl and atracurium.
Cost was calculated in euros/1 hour. Disposable cost was calculated in euros. In this group BIS sensor and TOF monitoring was used.</description>
          </group>
        </group_list>
        <measure>
          <title>Costs of Anaesthesia</title>
          <description>total cost of drugs (midazolam, propofol 1%, sevoflurane, atracurium, diclofenac, nalbuphin and antidotes) and disposable cost in euros</description>
          <units>euros</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>total cost of anaesthesia</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>total cost of anaesthesia</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total drug cost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.84" spread="4.11"/>
                    <measurement group_id="O2" value="7.86" spread="3.54"/>
                    <measurement group_id="O3" value="8.33" spread="3.02"/>
                    <measurement group_id="O4" value="7.52" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total disposable cost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="0.11"/>
                    <measurement group_id="O2" value="23.25" spread="0.12"/>
                    <measurement group_id="O3" value="8.09" spread="0.07"/>
                    <measurement group_id="O4" value="24.76" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total cost of anaesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.15" spread="5.32"/>
                    <measurement group_id="O2" value="19.95" spread="8.53"/>
                    <measurement group_id="O3" value="13.23" spread="4.23"/>
                    <measurement group_id="O4" value="22.11" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was carried out with SPSS version 21 for Windows (IBM Corporation) software. All data are expressed as means ± SD. Mann-Whitney test was performed to assess the differences between patient subgroups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The P value less than 0.05 was considered to be significant. With type I α = 5% and with type II (power) of 90%, we therefore needed 27 patients/group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
Fentanyl consumption was studied during anaesthesia. It was registered in milligram.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
Fentanyl consumption was studied during anaesthesia. It was registered in milligram.</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol). Fentanyl consumption was studied during anaesthesia. It was registered in milligram.</description>
        </group>
        <group group_id="E4">
          <title>Group D</title>
          <description>During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol). Fentanyl consumption was studied during anaesthesia. It was registered in milligram.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>other minor complications of anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study is restricted to anaesthesia of otorhinolaryngological surgery with controlled hypotension. Therefore, we cannot draw any conclusions related to other surgeries.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Timea Bocskai</name_or_title>
      <organization>Department of Anaesthesiology and Intensive Therapy, University of Pecs</organization>
      <phone>36 72 507374</phone>
      <email>bocskai.timea@pte.hu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

